Parkinson's disease: Recent development in therapies for advanced disease with a focus on deep brain stimulation (DBS) and duodenal levodopa infusion

FEBS Journal

Volumn 275, Issue 7, 2008, Pages 1370-1376

  Sydow, Olof ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

'on off'; CDS; DBS; Deep brain stimulation; Duodenal infusion; Duodopa ; Fluctuations; L dopa; Levodopa; Parkinson's disease

Indexed keywords

APOMORPHINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; ROTIGOTINE;

ADD ON THERAPY; BASAL GANGLION; CONTINUOUS INFUSION; DRUG EFFICACY; DYSKINESIA; HUMAN; MOTOR CORTEX; ON OFF PHENOMENON; PARKINSON DISEASE; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; PRIORITY JOURNAL; SHORT SURVEY; SUBTHALAMIC NUCLEUS; SYMPTOMATOLOGY; THALAMOCORTICAL TRACT; TREATMENT INDICATION; TREATMENT OUTCOME;

ANIMALS; ANTIPARKINSON AGENTS; DEEP BRAIN STIMULATION; DUODENUM; HUMANS; INFUSION PUMPS; LEVODOPA; PARKINSON DISEASE;

EID: 40749123608     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2008.06295.x     Document Type: Short Survey

References (47)

1. Daniel SE Lees AJ (1993) Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm 39, 165 172.
2. Scherfler C, Schwarz J, Antonini A, Grosset D, Valldeoriola F, Marek K, Oertel W, Tolosa E, Lees AJ Poewe W (2007) Role of DAT-SPECT in the diagnostic work up of Parkinsonism. Mov Disord 22, 1229 1238.
3. Carlsson A, Lindqvist M Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180, 1200.
4. Cotzias GC, Van Woert MH Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 276, 374 379.
5. Cotzias GC, Papavasiliou PS Gellene R (1969) L-dopa in parkinson's syndrome. N Engl J Med 281, 272.
6. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342, 1484 1491.
7. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B et al. (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61, 1044 1053.
8. Schade R, Andersohn F, Suissa S, Haverkamp W Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356, 29 38.
9. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356, 39 46.
10. Pontone G, Williams JR, Bassett SS Marsh L (2006) Clinical features associated with impulse control disorders in Parkinson disease. Neurology 67, 1258 1261.
11. Chase TN, Mouradian MM, Fabbrini G Juncos JL (1988) Pathogenetic studies of motor fluctuations in Parkinson's disease. J Neural Transm 27, 3 10.
12. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E Chase TN (1988) Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann Neurol 24, 366 371.
13. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ Chase TN (1988) Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II. Ann Neurol 24, 372 378.
14. Shoulson I, Glaubiger GA Chase TN (1975) On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25, 1144 1148.
15. Quinn N, Marsden CD Parkes JD (1982) Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa. Lancet 2, 412 415.
16. Quinn N, Parkes JD Marsden CD (1984) Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 34, 1131 1136.
17. Stocchi F, Ruggieri S, Brughitta G Agnoli A (1986) Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation. J Neural Transm 22, 209 218.
18. Olanow CW, Obeso JA Stocchi F (2006) Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nat Clin Pract 2, 382 392.
19. Olanow CW, Obeso JA Stocchi F (2006) Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 5, 677 687.
20. Chase TN (1998) Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 50, S17 S25.
21. Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F et al. (2004) Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 19, 997 1005.
22. Nutt JG (2007) Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa? Mov Disord 22, 1 9.
23. Spiegel EA, Wycis HT, Marks M Lee AJ (1947) Stereotaxic apparatus for operations on the human brain. Science 106, 349 350.
24. Hassler R Riechert T (1954) Indikationen und lokalisationsmethode der gezielten hirnoperationen. Nervenarzt 25, 441 447.
25. Svennilson E, Torvik A, Lowe R Leksell L (1960) Treatment of parkinsonism by stereotatic thermolesions in the pallidal region. A clinical evaluation of 81 cases. Acta Psychiatr Scand 35, 358 377.
26. Laitinen LV, Bergenheim AT Hariz MI (1992) Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 76, 53 61.
27. Benabid AL, Pollak P, Louveau A, Henry S de Rougemont J (1987) Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 50, 344 346.
28. Benabid AL, Pollak P, Seigneuret E, Hoffmann D, Gay E Perret J (1993) Chronic VIM thalamic stimulation in Parkinson's disease, essential tremor and extra-pyramidal dyskinesias. Acta Neurochirurg 58, 39 44.
29. Benazzouz A Hallett M (2000) Mechanism of action of deep brain stimulation. Neurology 55, S13 S16.
30. Schuurman PR, Bosch DA, Bossuyt PM, Bonsel GJ, van Someren EJ, de Bie RM, Merkus MP Speelman JD (2000) A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Med 342, 461 468.
31. Rehncrona S, Johnels B, Widner H, Tornqvist AL, Hariz M Sydow O (2003) Long-term efficacy of thalamic deep brain stimulation for tremor: double-blind assessments. Mov Disord 18, 163 170.
32. Sydow O, Thobois S, Alesch F Speelman JD (2003) Multicentre European study of thalamic stimulation in essential tremor: a six year follow up. J Neurol Neurosurg Psychiatry 74, 1387 1391.
33. Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin PD, Benazzouz A, LeBas JF et al. (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 349, 1925 1934.
34. Pollak P, Fraix V, Krack P, Moro E, Mendes A, Chabardes S, Koudsie A Benabid AL (2002) Treatment results: Parkinson's disease. Mov Disord 17 (Suppl. 3 S75 S83.
35. Volkmann J, Allert N, Voges J, Sturm V, Schnitzler A Freund HJ (2004) Long-term results of bilateral pallidal stimulation in Parkinson's disease. Ann Neurol 55, 871 875.
36. Ostergaard K, Sunde N Dupont E (2002) Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations. Mov Disord 17, 693 700.
37. Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H, Botzel K, Daniels C, Deutschlander A, Dillmann U, Eisner W et al. (2006) A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 355, 896 908.
38. Stefani A, Lozano AM, Peppe A, Stanzione P, Galati S, Tropepi D, Pierantozzi M, Brusa L, Scarnati E Mazzone P (2007) Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. Brain 130, 1596 1607.
39. LeWitt PA, Lyons KE Pahwa R (2007) Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 68, 1262 1267.
40. Kurlan R, Nutt JG, Woodward WR, Rothfield K, Lichter D, Miller C, Carter JH Shoulson I (1988) Duodenal and gastric delivery of levodopa in parkinsonism. Ann Neurol 23, 589 595.
41. Kurlan R, Rubin AJ, Miller C, Rivera-Calimlim L, Clarke A Shoulson I (1986) Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 20, 262 265.
42. Sage JI, Trooskin S, Sonsalla PK, Heikkila R Duvoisin RC (1988) Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 24, 87 89.
43. Bredberg E, Nilsson D, Johansson K, Aquilonius SM, Johnels B, Nystrom C Paalzow L (1993) Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease. Eur J Clin Pharmacol 45, 117 122.
44. Syed N, Murphy J, Zimmerman T Jr., Mark MH Sage JI (1998) Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord 13, 336 338.
45. Nilsson D, Nyholm D Aquilonius SM (2001) Duodenal levodopa infusion in Parkinson's disease - long-term experience. Acta Neurol Scand 104, 343 348.
46. Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius SM Askmark H (2005) Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64, 216 223.
47. Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, Dal Fante M, Lopiano L Pezzoli G (2007) Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 22, 1145 1149.